Safety of intravenous lacosamide in hospitalized children and neonates
Epilepsia · 2023
DOI: 10.1111/epi.17676 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsia, 2023. Verfasst von Susan L Fong und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Child, Hospitalized. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of California Berkeley, Wolfson Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
Seizures are common in critically ill children and neonates, and these patients would benefit from intravenous (IV) antiseizure medications with few adverse effects. We aimed to assess the safety profile of IV lacosamide (LCM) among children and neonates.
Methods
This retrospective multicenter cohort study examined the safety of IV LCM use in 686 children and 28 neonates who received care between January 2009 and February 2020.
Results
Adverse events (AEs) were attributed to LCM in only 1.5% (10 of 686) of children, including rash ( n = 3, .4%), somnolence ( n = 2, .3%), and bradycardia, prolonged QT interval, pancreatitis, vomiting, and nystagmus ( n = 1, .1% each). There were no AEs attributed to LCM in the neonates. Across all 714 pediatric patients, treatment‐emergent AEs occurring in >1% of patients included rash, bradycardia, somnolence, tachycardia, vomiting, feeling agitated, cardiac arrest, tachyarrhythmia, low blood pressure, hypertension, decreased appetite, diarrhea, delirium, and gait disturbance. There were no reports of PR interval prolongation or severe cutaneous adverse reactions. When comparing children who received a recommended versus a higher than recommended initial dose of IV LCM, there was a twofold increase in the risk of rash in the higher dose cohort (adjusted incidence rate ratio = 2.11, 95% confidence interval = 1.02–4.38). Significance This large observational study provides novel evidence demonstrating the tolerability of IV LCM in children and neonates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- UCB Pharma, Slough, UK.
- Departments of Neurology and Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Pediatric Neurology, Department of Neurology, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Susan L Fong, Moninder Kaur, Nicholas S Abend, Réjean M Guerriero, Christopher B Forrest
Förderung
- University of California Berkeley
- Wolfson Foundation
Zitieren
APA
Fong, S. L., Utidjian, L., Kaur, M., Abend, N. S., Wainwright, M. S., Grande, K. M., Foskett, N., Roebling, R., Guerriero, R. M., Jain, B., Rao, S., Stoltenberg, M., Williams, P., Yuen, N., Dickinson, K., McDonald, J., Maltenfort, M., & Forrest, C. B. (2023). Safety of intravenous lacosamide in hospitalized children and neonates. Epilepsia. https://doi.org/10.1111/epi.17676
Vancouver
Fong SL, Utidjian L, Kaur M, Abend NS, Wainwright MS, Grande KM, et al. Safety of intravenous lacosamide in hospitalized children and neonates. Epilepsia. 2023. doi:10.1111/epi.17676
BibTeX
@article{Fong2023,
author = {Fong, Susan L and Utidjian, Levon and Kaur, Moninder and Abend, Nicholas S and Wainwright, Mark S and Grande, Krista M and Foskett, Nadia and Roebling, Robert and Guerriero, Réjean M and Jain, Badal and Rao, Suchitra and Stoltenberg, Meredin and Williams, Paulette and Yuen, Nancy and Dickinson, Kimberley and McDonald, Jill and Maltenfort, Mitchell and Forrest, Christopher B},
title = {Safety of intravenous lacosamide in hospitalized children and neonates},
journal = {Epilepsia},
year = {2023},
doi = {10.1111/epi.17676}
}
EUVIMED